🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Voyager Therapeutics, Inc. VYGR R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://www.voyagertherapeutics.com
Company Profile ↓
$3.38
-7.40% 1Y
Mkt Cap$208.27M
P/E-1.87
P/B1.14
52W High$5.33
52W Low$3.00
Book Value$2.88
EPS (TTM)$-1.81

Company Overview

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.20.

Recent Developments

  • Dec 2025 Revenue of $40.37M (-49.5% YoY); net profit $-119.72M.
  • Trailing 12 Months Year-on-year growth — revenue -59.9%.
  • 5-Year Trend Long-term compounding — revenue CAGR 8.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:8.82%
1 Year:-59.90%

Stock Price Performance

1 Year:-7.40%
6 Months:-13.33%
3 Months:+1.50%
1 Month:+7.99%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 16% of range
$3.00 $5.33
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)51.17 · Neutral
Price Performance
1M+7.99%
3M+1.50%
6M-13.33%
1Y-7.40%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

No notable strengths flagged.

CONS

  • Trading 36.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-1.87
Industry PE
25.17
Forward P/E
-2.17
PEG Ratio
-
Book Value
$2.88
Price to Book
1.14
P/S
5.52
EV/EBITDA
-0.69
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
8.82%
Profit 5Y
-
Revenue (YoY)
-59.90%
Earnings (YoY)
-

Profitability & Returns

ROCE
-58.41%
ROE
-52.26%
ROA
-27.05%
Profit Margin
0.00%
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-0.40
EPS (TTM)
$-1.81

Balance Sheet & Liquidity

Debt/Equity
0.20
Quick Ratio
8.20
Current Ratio
8.42
Debt
$34.57M
Total Assets
$197.75M
Current Assets
$146.98M
Working Capital
$176.15M

Ownership

Promoter Holding
14.84%
Chg in Prom Hold
-0.29%
FII / Inst Holding
57.87%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$208.27M
Total Revenue (TTM)
$36.49M
EBITDA
$-119.94M
Free Cash Flow
$-80.83M
Operating Cash Flow
$-127.99M
Shares Outstanding
61.62M
Gross Margin
-
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 VYGR Voyager Therapeutics, Inc. R2KR3KPHARMA 3.38 -1.87 $208.27M 0.00% -58.41% -52.26% 8.82% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue -------1.46M1.18M1.15M6.35M942.00K2.58M2.09M2.01M5.20M46.09M20.43M32.67M18.07M28.68M117.84M6.50M1.36M1.48M658.00K712.00K41.09M150.48M4.85M4.61M19.52M29.58M24.63M6.47M5.20M13.37M15.34M2.59M3.17M
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses ----------------------------------41.17M41.83M43.96M45.27M32.86M-
Operating Income -3.97M-4.02M-7.44M-7.47M-9.62M-10.37M-13.84M-17.52M-18.64M-23.36M-12.35M-21.09M-25.69M-21.15M-23.16M-29.29M9.19M-17.81M-13.77M-24.43M-8.98M84.53M-25.59M-28.59M-25.15M-21.35M-19.37M14.44M122.88M-25.43M-29.51M-16.18M-15.03M-13.78M-34.69M-36.62M-30.59M-29.93M-30.27M-26.39M
EBITDA -----------------------------------33.68M-35.56M-29.66M-28.88M-29.34M-
Interest Expense ----------------------------------------
Pretax Income -----------------------------------30.98M-33.37M-27.81M-27.42M-27.92M-
Tax Provision ----------------------------------37.00K15.00K83.00K9.00K14.00K-
Net Income -3.90M-3.92M--7.19M-9.34M-9.00M--16.65M-18.88M-23.35M-11.83M-19.93M-25.54M-20.29M-22.53M-27.17M11.15M-15.01M-12.57M-24.26M-8.68M85.61M-21.65M-30.12M-25.14M-21.32M-19.09M17.62M124.04M-22.21M-25.90M-11.33M-10.14M-9.04M-31.02M-33.38M-27.89M-27.43M-27.94M-24.47M
Diluted EPS -------------0.80---0.29-0.41---0.232.27-0.58-0.80-0.67-0.56-0.500.452.94-0.51-0.59-0.20-0.18-0.16-0.53-0.57-0.47-0.47-0.47-0.40
R&D Expense 6.46M6.48M-8.73M10.48M10.31M-14.07M15.30M19.56M-14.85M16.51M16.63M-24.83M28.58M29.78M-32.29M29.42M25.04M22.35M19.50M17.91M14.35M12.53M19.34M18.57M21.98M25.86M27.09M34.45M30.24M31.53M31.33M35.87M-24.60M22.04M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -17.33M14.22M10.13M7.62M104.39M171.13M37.41M40.91M250.01M80.00M40.37M
Cost of Revenue ------------
Gross Profit ------------
Operating Expenses --------91.74M127.99M163.29M172.22M
Operating Income -14.37M-20.25M-41.30M-71.86M-91.09M-51.68M27.38M-73.62M-50.84M122.01M-83.29M-131.84M
EBITDA ---------44.65M126.45M-78.56M-127.78M
Interest Expense ------------
Pretax Income ---------46.39M133.74M-64.34M-119.58M
Tax Provision --------16.00K1.41M665.00K144.00K
Net Income -16.32M-29.67M-40.19M-70.70M-88.29M-43.60M36.74M-71.20M-46.41M132.33M-65.00M-119.72M
Diluted EPS -----2.75-1.210.98-1.89-1.212.97-1.13-2.04
R&D Expense 8.90M27.68M42.25M62.26M64.91M119.73M108.75M73.79M60.76M92.17M127.37M134.67M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets -11.50M229.46M189.57M184.48M177.03M354.76M261.58M-159.36M351.28M393.05M252.28M
Current Assets ---------124.50M319.68M276.81M202.69M
Cash & Equivalents 135.00K7.04M31.31M36.64M31.53M46.86M86.04M104.44M-98.96M68.80M71.37M65.30M
Inventory -------------
Receivables ---------080.15M1.50M1.76M
Total Liabilities -10.35M60.38M53.64M50.43M130.58M255.25M107.26M-100.34M114.96M93.29M56.20M
Current Liabilities -2.47M23.93M13.80M15.90M31.67M76.01M26.77M-72.59M64.51M49.79M26.54M
Long Term Debt -------------
Total Debt ---------23.13M20.29M43.73M36.50M
Total Equity -3.83M-20.83M169.07M135.92M134.05M46.45M99.51M154.32M-59.02M236.32M299.76M196.08M
Shares Outstanding ---------38.61M44.04M54.73M59.05M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -41.30M-42.48M-61.35M-15.89M48.67M-96.72M--12.51M77.92M-15.31M-132.47M
Investing Cash Flow --194.77M47.72M-3.68M26.47M-90.48M113.00M--7.34M-141.64M-94.86M125.45M
Financing Cash Flow -177.74M514.00K59.92M4.75M80.99M3.16M-1.11M33.65M114.02M816.00K
Capital Expenditure -2.99M-1.03M-5.03M-3.98M-4.30M-7.72M-12.10M--2.49M-3.26M-3.52M-2.60M
Free Cash Flow -40.27M-47.51M-65.33M-20.19M40.95M-108.81M--15.00M74.66M-18.83M-135.06M
Net Change in Cash ---------18.74M-30.08M3.85M-6.21M

Ratios (Annual)

Figures in %.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ------------
Operating Margin % --116.8%-290.4%-709.1%-1,195.6%-49.5%16.0%-196.8%-124.3%48.8%-104.1%-326.6%
Net Margin % --171.2%-282.7%-697.6%-1,158.8%-41.8%21.5%-190.3%-113.4%52.9%-81.3%-296.5%
ROE % 78.3%-17.5%-29.6%-52.7%-190.1%-43.8%23.8%--78.6%56.0%-21.7%-61.1%
ROCE % -159.2%-9.9%-23.5%-42.6%-62.7%-18.5%11.7%--58.6%42.5%-24.3%-58.4%

Shareholding Pattern

Insiders
14.84%
Institutions
57.87%
Public Float
67.95%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 8.39% 5.17M $18.31M
2 Millennium Management Llc 7.21% 4.44M $15.73M
3 Armistice Capital, LLC 5.58% 3.44M $12.16M
4 Vestal Point Capital, LP 4.26% 2.62M $9.29M
5 Vanguard Capital Management LLC 3.81% 2.35M $8.30M
6 Geode Capital Management, LLC 2.16% 1.33M $4.71M
7 Opaleye Management Inc. 1.92% 1.19M $4.19M
8 State Street Corporation 1.75% 1.08M $3.81M
9 Two Sigma Investments, LP 1.54% 948.52K $3.36M
10 Dimensional Fund Advisors LP 1.36% 838.18K $2.97M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for VYGR

Yahoo Finance ue, 01 Sep 2026

Voyager to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in th…

Yahoo Finance hu, 06 Aug 2026

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of +27.27% and -9.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo Finance Mon, 13 Jul 2026

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseas…

Yahoo Finance hu, 02 Jul 2026

Cramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make Money

On the June 30 episode of Mad Money, a 23-year-old caller named Jackson from Iowa asked Jim Cramer about Voyager Therapeutics (NASDAQ:VYGR), a clinical-stage gene therapy company he wanted to hold for the long haul. Cramer’s response was a …

Yahoo Finance ue, 30 Jun 2026

Voyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% Upside

Voyager Therapeutics Inc. (NASDAQ:VYGR) is one of the 10 best stocks under $10 offering more than 50% upside. Back on June 1, Voyager Therapeutics Inc. (NASDAQ:VYGR) received FDA approval for VY1706, a gene therapy for Alzheimer’s that targ…

Yahoo Finance Mon, 29 Jun 2026

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced a Developing Topics (late-breaking) post…

VYGR — Frequently Asked Questions

What is the current share price of Voyager Therapeutics, Inc. (VYGR)?

As of 2026-09-07 16:24 PDT, Voyager Therapeutics, Inc. (VYGR) trades at $3.38 on NasdaqGS. Its 52-week range is $3.00 to $5.33.

What is the market capitalisation of VYGR?

Voyager Therapeutics, Inc. (VYGR) has a market capitalisation of $208.27M on NasdaqGS.

What is the P/E ratio of VYGR?

VYGR trades at a trailing price-to-earnings (P/E) ratio of -1.87. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 1.14.

What is the return on equity (ROE) of VYGR?

VYGR has a return on equity (ROE) of -52.26%. Its return on capital employed (ROCE) is -58.41%.

Is VYGR a good stock to buy?

This page provides a data-driven analysis of Voyager Therapeutics, Inc. (VYGR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space